Login to Your Account



Early Stage p53 Program Lands Ascenta $398M Deal with Sanofi

By Jennifer Boggs


Monday, June 7, 2010
In its first major collaboration since being founded in 2003, privately held Ascenta Therapeutics Inc. partnered an early stage cancer program with Sanofi-Aventis SA in exchange for up to $398 million in up-front and milestone payments, plus tiered royalties on any products that make it to market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription